Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
List view / Grid view
Articles
Turning rare diseases into efficient targets with AI
BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution...
Q&A: Lou Matis on bispecific antibodies
Drug Target Review Editor Steve Bremer talks to Pieris’ Chief Development Officer Lou Matis about bispecific antibodies.
Targeting GAS6 in cancer, fibrosis and viral infection
The growth-arrest specific 6 (GAS6) protein has emerged in recent years as an attractive target for drug development primarily because it is the sole ligand for the AXL receptor tyrosine kinase, which plays critical roles in cancer, fibrosis, and viral infection.
Nanoparticle-mediated enzyme delivery for application in cancer therapy
Enzyme therapy is a promising form of cancer treatment. The specific nature of enzyme and substrate interaction gives enzyme therapy an edge compared to standard non-specific therapies such as radiation and chemotherapy. However, since most of these enzymes are of a foreign nature, the delivery of these immunogenic enzymes has…
Drug Target Review – Issue #1 2017
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
Developability assessment of therapeutic antibodies
Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…
Towards systems biomarkers for cancer diagnosis
Cancer is asymptomatic during most of its pathogenesis. It is very difficult to see that a cancer is growing in a person, except for a few self-evident cases such as skin cancer. Its intangibility and year-, if not decade-long progression make cancer hard to diagnose until some symptoms warrant further…
Whole animal screening: back to the future
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
Product Hub: The growing potential of hiPS-derived beta cells
Christian Andersson, Product Development Manager at Takara Bio discusses hiPS-derived beta cells, which offer an unprecedented opportunity for diabetes research to model human physiology and ‘diseases in a dish’. Christian looks into the potential for new discoveries for diabetes and other metabolic diseases...
Product Hub: Flow cytometric screening assays in drug discovery
Flow cytometry is a laser-based technology – a powerful tool for drug discovery and the screening process and can be used in all settings, including research, clinical, pharmaceutical and biotechnology. The increasing capabilities of flow cytometers make their incorporation into drug development and screening optimal...
Democratising clinical genomics while protecting data privacy
Sophia Genetics co-founder and CEO, Jurgi Camblong, tackles issues of privacy and security for healthcare patient data...
How Ketamine could cure depression
Amorsa Therapeutics' CSO, Michael Palfreyman, discusses how the party drug Ketamine can be used to target NMDA receptors and treat depression...
How imaging biomarkers are transforming drug development
Drug developers sometimes think of imaging as an emerging discipline, full of esoteric technologies of marginal relevance to real-world clinical drug development. In fact, the opposite is true: imaging measurements (imaging biomarkers) are used daily in drug development and in personalised medicine. They assess target engagement and receptor occupancy in…
Draper and Pfizer partner on human organ-on-a-chip technology
The companies will collaborate to create unique versions of Draper’s Microphysiological Systems (MPS) technology, with the aim of creating more effective disease models...
